Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex
pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains …

Atopic dermatitis (AD) is a chronic inflammatory skin disorder associated with heterogenous
presentation and often immense patient burden. Safe, targeted treatment options are …

Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in
hair loss, that affects up to 2% of the general population. The exact pathobiology of AA has …

Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …

Background Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic
efficacy in a phase 2 study in adults with atopic dermatitis (AD). Objective To evaluate 8 …

Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced
atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids …

The discovery of cytokines as key drivers of immune-mediated diseases has spurred efforts
to target their associated signalling pathways. Janus kinases (JAKs) are essential signalling …

Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit
proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been …

Atopic dermatitis (AD) is a common inflammatory skin condition that has traditionally been
considered a paradigmatic type 2 immunity (T2)‐driven disease. Interleukin (IL)‐4 and IL‐13 …

Recent advances in the pathophysiologic understanding of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has indicated that patients with severe …